دورية أكاديمية
MicroRNA-30 and 145 as Targets for the Treatment of Cardiovascular Diseases: Therapeutic Feasibility and Challenges.
العنوان: | MicroRNA-30 and 145 as Targets for the Treatment of Cardiovascular Diseases: Therapeutic Feasibility and Challenges. |
---|---|
المؤلفون: | Tolouei SEL; Laboratory of Reproductive Toxicology, Department of Pharmacology, Federal University of Paraná (UFPR), Curitiba, PR, Brazil., Curi TZ; Laboratory of Electrophysiology and Cardiovascular Pharmacology, Faculty of Health Sciences, Federal University of Grande Dourados (UFGD), Dourados, MS, Brazil., Klider LM; Laboratory of Reproductive Toxicology, Department of Pharmacology, Federal University of Paraná (UFPR), Curitiba, PR, Brazil., Junior AG; Laboratory of Reproductive Toxicology, Department of Pharmacology, Federal University of Paraná (UFPR), Curitiba, PR, Brazil. |
المصدر: | Current pharmaceutical design [Curr Pharm Des] 2021; Vol. 27 (37), pp. 3858-3870. |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Review |
اللغة: | English |
بيانات الدورية: | Publisher: Bentham Science Publishers Country of Publication: United Arab Emirates NLM ID: 9602487 Publication Model: Print Cited Medium: Internet ISSN: 1873-4286 (Electronic) Linking ISSN: 13816128 NLM ISO Abbreviation: Curr Pharm Des Subsets: MEDLINE |
أسماء مطبوعة: | Publication: Saif Zone, Sharjah, U.A.E. : Bentham Science Publishers Original Publication: Schiphol, The Netherlands : Bentham Science Publishers, c1995- |
مواضيع طبية MeSH: | Cardiovascular Diseases*/drug therapy , Cardiovascular Diseases*/genetics , Cardiovascular System* , MicroRNAs*/genetics, Feasibility Studies ; Heart ; Humans |
مستخلص: | Cardiovascular diseases (CVDs) are a group of non-communicable disorders of the heart and blood vessels. Although lifestyle changes as well as pharmacological treatments and surgical interventions are available in many countries, CVDs are still considered the number one cause of mortality worldwide. Hence, considering that most CVDs are caused by genetic and environmental imbalances, micro-RNAs (miRNAs or miRs) appear as a plausible therapeutic option for CVDs as they are able to regulate a wide number of genes due to multiple target sites in different genes. Since miRNA-30 and -145 have been shown to play critical roles in the cardiovascular system, acting as important regulators of many functions and biological processes, this review focuses on summarizing recent findings on their involvement in CVDs, mainly as targets for therapeutic intervention. Therefore, the biology, mechanisms of action and data on what has been discovered so far regarding miRNA-30 and 145 as therapeutic targets for CVDs are presented. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.) |
معلومات مُعتمدة: | 59/300.046/2015, 71/700.135/2018 Fundação de Apoio ao Desenvolvimento do Ensino, Ciência e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT, Brazil); 449464/2014-8, 407685/2018-9 Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Brazil) |
فهرسة مساهمة: | Keywords: Epigenetics; RNA therapy; heart diseases; non-communicable disorders; small non-coding RNAs; vascular diseases. |
المشرفين على المادة: | 0 (MIRN30a microRNA, human) 0 (MicroRNAs) |
تواريخ الأحداث: | Date Created: 20201214 Date Completed: 20211207 Latest Revision: 20211214 |
رمز التحديث: | 20221213 |
DOI: | 10.2174/1381612826666201211120822 |
PMID: | 33308116 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1873-4286 |
---|---|
DOI: | 10.2174/1381612826666201211120822 |